Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-25T16:59:40.887Z Has data issue: false hasContentIssue false
  • English
  • Français

Proton therapy in craniospinal irradiation: a systematic review

Published online by Cambridge University Press:  21 September 2015

Adam I. Husak  and
Pete Bridge
Adam I. Husak
Affiliation:
Cancer Care Services, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
Pete Bridge*
Affiliation:
Cancer Care Services, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
*
Correspondence to: Pete Bridge, Directorate of Medical Imaging and Radiotherapy, University of Liverpool, Brownlow Hill, Liverpool L69 3GB, UK. Tel: (+44) 0151 7958366; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim

Craniospinal irradiation is a technique indicated when a patient has a malignancy that has either disseminated, or is at risk of disseminating, throughout the subarachnoid space. While the craniospinal axis is treatable with conventional radiotherapy, the high doses to organs at risk carry an increased risk of acute and late side effects. Proton craniospinal irradiation is an expensive technique that shows great theoretical promise arising from reduced exit doses. The purpose of this systematic review is to determine the potential role of proton therapy as a standard modality for craniospinal irradiation.

Materials and methods

A literature review was performed to determine the efficacy and cost of proton craniospinal irradiation. The Cochrane Library and the Inspec, Medline (via Pubmed) and Scopus databases were searched. After exclusion criteria were applied, the remaining papers were systematically appraised utilising the Scottish Intercollegiate Guidelines Network critical appraisal checklists.

Results

A total of 14 articles remained following the application of the screening and critical appraisal processes. In total, five of the articles concluded that the risk of secondary malignancy was lower with proton therapy, while ten of the articles included data showing that toxicity rates and organs at risk doses were lower with proton therapy. Doses to most thoracic and abdominal organs at risk analysed in the literature were reduced when proton therapy was used, with the sole exception of the oesophagus, the dose to which depended on whether or not the entire vertebral body was treated. Proton therapy also delivered optimal doses to organs at risk in the head and neck compared with conformal radiation therapy. However, in one study that compared tomotherapy to proton therapy, tomotherapy outperformed proton therapy by delivering lower doses to organs at risk in the head and neck, as well as the kidneys. The two cost-effectiveness studies did not indicate proton therapy as an optimal modality for all treatment sites; however, one of the studies found that for medulloblastoma, protons were more cost effective than conventional radiation therapy.

Findings

Proton therapy is a superior treatment option for craniospinal irradiation. The reduction in risk of toxicity and radiocarcinogenesis offered by proton craniospinal irradiation appear to outweigh the increased costs.

Keywords

craniospinalmedulloblastomaprotonradiotherapy
Type
Literature Reviews
Information
Journal of Radiotherapy in Practice , Volume 15 , Issue 2 , June 2016 , pp. 196 - 202
Check for updates
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Barrett, A, Dobbs, J, Morris, S, Roques, T. Practical Radiotherapy Planning, 4th edition. London: Hodder Arnold Publishing, 2008.Google Scholar
2.Fossati, P, Ricardi, U, Orrechia, R. Pediatric medulloblastoma: toxicity of current treatment and potential role of proton therapy. Cancer Treat Rev 2009; 35 (1): 79–96.Google Scholar
3.Lodge, M, Pijls-Johannesma, M, Stirk, L, Munro, A J, de Ruysscher, D, Jefferson, T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol 2007; 83 (2): 110–122.CrossRefGoogle ScholarPubMed
4.Healthcare Improvement Scotland. Critical Appraisal: Notes and Checklists. 2014. http://www.sign.ac.uk/methodology/checklists.html. Accessed on 26th December 2014.Google Scholar
5.Brodin, N, Rosenschöld, P M, Aznar, M Cet al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol 2011; 50 (6): 806–816.Google Scholar
6.Brown, A P, Barney, C L, Grosshans, D Ret al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 2013; 86 (2): 277–284.Google Scholar
7.Howell, R M, Giebeler, A, Koontz-Raisig, Wet al. Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. Radiat Oncol 2012; 7 (1): 116.CrossRefGoogle ScholarPubMed
8.Lee, C T, Bilton, S D, Famiglietti, R Met al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 2005; 63 (2): 362–372.Google Scholar
9.Lester-Coll, N H, Morse, C B, Zhai, H Aet al. Preserving fertility in adolescent girls and young women requiring craniospinal irradiation: a case report and discussion of options to be considered prior to treatment. J Adolesc Young Adult Oncol 2014; 3 (2): 96–99.Google Scholar
10.Peréz-Andújar, A, Newhauser, W D, Taddei, P J, Mahajan, A, Howell, R M. The predicted relative risk of premature ovarian failure for three radiotherapy modalities in a girl receiving craniospinal irradiation. Phys Med Biol 2013; 58 (10): 3107–3123.Google Scholar
11.Pijls-Johannesma, M, Pommier, P, Lievens, Y. Cost-effectiveness of particle therapy: current evidence and future needs. Radiother Oncol 2008; 89 (2): 127–134.Google Scholar
12.St. Clair, W H, Adams, J A, Bues, Met al. Advantages of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004; 58 (3): 727–734.CrossRefGoogle ScholarPubMed
13.Stokkevåg, C H, Engeseth, G, Ytre-Hauge, K Set al. Estimated risk of radiation-induced cancer following paediatric cranio-spinal irradiation with electron, photo and proton therapy. Acta Oncol 2014; 53 (8): 1048–1057.Google Scholar
14.Yoon, M, Shin, D H, Kim, Jet al. Craniospinal irradiation techniques: a dosimetric comparison of proton beams with standard and advanced photon radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81 (3): 637–646.Google Scholar
15.Zhang, R, Howell, R M, Giebeler, A, Taddei, P J, Mahajan, A, Newhauser, W D. Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient. Phys Med Biol 2013; 58 (4): 807–823.Google Scholar
16.Zhang, R, Howell, R M, Homann, Ket al. Predicted risks of radiogenic cardiac toxicity in two pediatric patients undergoing photon or proton radiotherapy. Radiat Oncol 2013; 8 (1): 184–193.Google Scholar
17.Zhang, R, Howell, R M, Taddei, P J, Giebeler, A, Mahajan, A, Newhauser, W D. A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation. Radiother Oncol 2014; 133 (1): 84–88.Google Scholar